Anixa Biosciences, Inc. Overview
Pro stress-test →Anixa Biosciences is a clinical-stage biotech company developing CAR-T immunotherapies and cancer vaccines. The company is engineering patient immune cells to fight cancer and developing a revolutionary vaccine targeting breast cancer, with expansion into ovarian and other solid tumors.
Strategic Profile
Pro stress-test →Anixa leverages partnerships with world-renowned research institutions like Moffitt Cancer Center and Cleveland Clinic to advance its programs, creating a capital-efficient development model. The company focuses on addressing critical unmet needs in oncology through novel mechanisms using "retired" protein targets that differentiate it in the competitive immunotherapy space.
Competitive Landscape
Pro stress-test →Anixa competes in the CAR-T immunotherapy and cancer vaccine space against major players like Juno Therapeutics (Celgene), Novartis, and emerging biotech firms. Its differentiation lies in the novel CER-T platform using natural hormone ligands and proprietary retired-protein vaccine technology. The company's institutional partnership model provides clinical credibility while maintaining capital efficiency relative to fully-integrated competitors.
Industry Context
Anixa Biosciences, Inc. operates in Biotechnology - Oncology Therapeutics & Vaccines.
Key facts
Founded: 1982 · Headquarters: San Jose, California · Employees: 4